You just read:

Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)

News provided by

Viking Therapeutics, Inc.

14 Feb, 2017, 07:05 ET